Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.

Research at Baruch S Blumberg Institute has led to the discovery of new diazepine derivatives targeting yellow fever virus nonstructural protein 4B (NS4B) for the treatment of yellow fever virus infections.

Flare Therapeutics Inc. has patented peroxisome proliferator-activated receptor γ (PPARγ, PPARG) inverse agonists reported to be useful for the treatment of bladder cancer.

Researchers at Firefly Bio Inc. have prepared antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting HER2 covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, inflammation and infections.

Several Insilico Medicine Inc. patents describe diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer and viral infection.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified 3-alkynyl carboxamides acting as legumain (asparaginyl endopeptidase; LGMN) inhibitors.

Medshine Discovery Inc. has synthesized nitrogen-containing heterocyclic compounds acting as tyrosine-protein kinase JAK3 and Tec inhibitors.

Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have jointly described new phosphatidylinositol 3-kinase (PI3K) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Immuther Pharmtech (Shanghai) Co. Ltd. has patented lysophosphatidic acid LPA5 receptor (GPR92) antagonists reported to be useful for the treatment of neuropathic pain, cancer, neurological disorders, atherosclerosis, inflammatory and autoimmune diseases, fibrosis and obesity, among others.